{"nctId":"NCT02319031","briefTitle":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","startDateStruct":{"date":"2015-02"},"conditions":["Hepatitis C"],"count":53,"armGroups":[{"label":"Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Daclatasvir","Drug: Sofosbuvir","Drug: Ribavirin"]},{"label":"Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Daclatasvir","Drug: Sofosbuvir","Drug: Ribavirin"]}],"interventions":[{"name":"Daclatasvir","otherNames":[]},{"name":"Sofosbuvir","otherNames":[]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Must have Genotype 3 Chronic HCV\n* Must have advanced fibrosis (F3) or compensated cirrhosis (F4)\n* HCV RNA Viral load â‰¥ 10,000 IU/mL\n* HCV Treatment naive or treatment-experienced\n\nExclusion Criteria:\n\n* Non Genotype 3 or mixed genotypes\n* Non advanced fibrosis or compensated cirrhosis\n* Any prior treatment with NS5A inhibitors","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)","description":"SVR12, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \\< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 12. SVR12 imputation was based on Next Value Carried Backwards (NVCB) approach. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)","description":"SVR4, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \\< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 4. SVR24, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \\< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 24. SVR4 imputation was based on Next Value Carried Backwards (NVCB) approach. SVR24 imputation was based on missing being treated as non-responder. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities","description":"Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. The degree of the adverse event or laboratory abnormality are evaluated by grades: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Grading as per using National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0 criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":24},"commonTop":["Insomnia","Fatigue","Headache","Irritability","Asthenia"]}}}